I saw the slide 4 mention. We're talking specifically about the AD prevention trial planning. The slide 4 vague statement and link is not exactly that but clearly something they're comfortable with. The preclinical support cited by the company was for AD; hopefully there is preventive potential for other neuro-degenerative indications (eg PDD). This may also come in the future.
Market Data 
Markets 
AI
